GALAPAGOS NV-SPON ADR (GLPG) Stock News
NASDAQ:GLPG - Nasdaq - US36315X1019 - ADR - Currency: USD
GLPG Latest News, Press Relases and Analysis
Galapagos Announces CFO Exit With No Successor Named Yet: Retail’s Disappointed
The company expects to announce a new CFO “in the coming months.”
Is Galapagos (GLPG) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?
We recently published a list of Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn. In this article, we are going to take a look at where Galapagos NV (NASDAQ:GLPG) stands against other top healthcare stocks to buy according to Billionaire David Einhorn. Wall Street has come down crashing on President Donald Trump’s […]
Biotech stocks slide as Marks resignation seen being negative for sector
Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit
GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Galapagos (NASDAQ:GLPG) just reported results for the second quarter of 2024.Ga...
GLPG Stock Earnings: Galapagos Beats EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Galapagos (NASDAQ:GLPG) just reported results for the first quarter of 2024.Gal...
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
The company is gearing up to rival giants Gilead and Novartis with a potentially decentralized CAR-T process.
GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q3 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Galapagos (NASDAQ:GLPG) just reported results for the third quarter of 2023.Gal...
GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q2 2024
GLPG stock results show that Galapagos beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology
/PRNewswire/ -- BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditionally "hard-to-drug" targets, today announced an...
GLPG Stock Earnings: Galapagos Beats EPS, Misses Revenue for Q1 2024
GLPG stock results show that Galapagos beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
Galapagos enters into strategic collaboration with Thermo Fisher (NASDAQ:GLPG)
Galapagos NV enters strategic collaboration with Thermo Fisher for decentralized manufacturing of CAR-T product in San Francisco area, effective January...
Galapagos signs development deal with BridGene (NASDAQ:GLPG)
Galapagos (GLPG) has entered into a strategic collaboration deal with BridGene Biosciences, with Galapagos receiving the exclusive right to commercialize any resulting products.
BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets
/PRNewswire/ -- BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditional "hard-to-drug" targets, announced today a...
Galapagos to transfer Jyseleca business to Alfasigma (NASDAQ:GLPG)
Galapagos (GLPG) Tuesday said it entered into a deal to sell its Jyseleca business to Italian pharma company Alfasigma. Per the terms, Galapagos will receive a €50 million payment upfront..
GLPG Stock Earnings: Galapagos Beats EPS, Beats Revenue for Q3 2023
GLPG stock results show that Galapagos beat analyst estimates for earnings per share and beat on revenue for the third quarter of 2023.